ZVSA
ZyVersa Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.10
−0.20%Year over year
Reported trailing growth
- Revenue
- -100.0%
- EBITDA
- —
- EBIT
- +199.3%
- EPS
- +57.3%
- Free cash flow
- +46.0%
- Operating cash flow
- +67.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- +99.7%
- EBIT
- +99.9%
- Net income
- +99.7%
- EPS
- +50.7%
- Free cash flow
- +32.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026